CWM
ACRS icon

CIBC World Markets’s Aclaris Therapeutics ACRS Stock Holding History

CIBC World Markets’s Portfolio ACRS Stock Details ACRS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		$15.9K Buy
+11,184
New +$15.1K ﹤0.01% 1537

Other funds holding ACRS

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

CIBC World Markets's ACRS Position: Q2 2025 in Review

CIBC World Markets opened a new position in Aclaris Therapeutics (ACRS) in Q2 2025: 11,184 shares worth $15.9K. The stake represents ﹤0.01% of the portfolio and ranks #1537 among its holdings.

96 funds tracked by Wall St. Rank hold ACRS as of Q2 2025.

  • CIBC World Markets held 11,184 shares of Aclaris Therapeutics worth $15.9K as of Q2 2025.
  • Aclaris Therapeutics was a new CIBC World Markets position in Q2 2025.
  • Aclaris Therapeutics made up ﹤0.01% of CIBC World Markets's portfolio in Q2 2025, its #1537 holding.
  • 96 funds tracked by Wall St. Rank held Aclaris Therapeutics as of Q2 2025.

Based on CIBC World Markets's 13F filing for Q2 2025, filed 14 Aug 2025.